SenoGram named winner in 2023 Artificial Intelligence Excellence Awards
The Artificial Intelligence Excellence Awards—a program that recognizes organizations and products that bring AI to life—selected Seno Medical’s AI platform in the Diagnosis category for 2023. The company’s AI platform, SenoGram, is an artificial intelligence (AI) decision-support tool that reportedly helps physicians interpret new images from the Imagio System, another product by Seno Medical. According to the company, SenoGram, along with training and certification, helps radiologists transition from ultrasound alone to OA/US imaging to more accurately determine the likelihood of malignancy of breast lesions.
Breast biopsy procedures caused by false-positive diagnostic assessments cost the U.S. healthcare system more than $2 billion per year. According to the company, their Imagio technology could help to reduce those costs with its OA/US system.
The Imagio System was cleared by the US FDA in 2021 and received Supplemental PMA Approval for its market-ready device in June 2022. The system is indicated for use by trained and qualified healthcare providers to evaluate palpable and non-palpable breast abnormalities in adult patients who are referred for diagnostic imaging breast work-up following clinical presentation or other imaging examinations such as screening mammography.
“We are delighted to be included among these groundbreaking leaders in the artificial intelligence stratosphere,” Tom Umbel, Seno’s CEO, commented. “The use of the SenoGram is a tremendous benefit to clinicians in interpreting the images from Imagio. Our AI advancements improve outcomes for patients and increase diagnostic confidence of providers.”
Recently honored with a Gold Edison award—a Gold Medical Design Excellence Award—and as a semifinalist in the 2022 Minnies, Seno Medical’s diagnostic breast cancer imaging system uses non-invasive opto-acoustic/ultrasound (OA/US) technology to provide information on breast lesions in real time, helping providers to characterize masses that may or may not require more invasive diagnostic evaluation.
According to the company, Seno’s OA/US system combines laser optics and grayscale ultrasound to provide fused functional, morphological, and anatomical breast imaging. The opto-acoustic images provide a blood map in and around breast masses, while the ultrasound provides a traditional anatomical image. Through the appearance or absence of two hallmark indicators of cancer—angiogenesis and hypoxia—Seno Medical’s Imagio OA/US Breast Imaging System is reportedly designed to help radiologists confirm or rule out malignancy compared with traditional diagnostic imaging modalities, and does so without exposing patients to potentially harmful ionizing radiation (x-rays) or contrast agents.
“We are so proud to name Seno Medical as a winner in our inaugural Artificial Intelligence Excellence Awards program,” said Maria Jimenez, Chief Nominations Officer for Business Intelligence Group. “It was clear to our judges that Seno was using AI to improve the lives of their customers and employees. Congratulations to the entire team!”